[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dna-methylation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dna-methylation":231},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,39,56,88,115,140,165,176,184,207],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100054214",false,"NCT06476067","Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma","Predicting Postoperative Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Patients who had histologically confirmed ESCC.\n2. Patients who had undergone only complete esophagectomy with radical lymph node dissection without chemotherapy or radiotherapy before or after surgery.\n3. Patients for whom tissue samples are available\n4. Patients who were followed-up completely, with information on observation periods of at least 2 years after surgery.\n5. Written informed consent following full study information is provided to the patient.\n\nExclusion Criteria:\n\n1. Patients lacking clinical information within 2 years of surgery.\n2. Patients with multiple cancers.","ALL","20 Years",{"count":18,"type":19},150,"ESTIMATED","OBSERVATIONAL","The prognosis of patients with esophageal squamous cell carcinoma (ESCC) who develop post-operative early tumor recurrence is often relatively poor. Therefore, biomarker that can detect micro metastases before the start of treatment is required. Epigenomic alterations such as DNA methylation have attracted attention as promising biomarkers. The investigators aim to predict early recurrence based on whole genome DNA methylation analysis of esophageal cancer.",[23,24,25],"Esophageal Cancer","Recurrence","DNA Methylation","RECRUITING","2026-07-10",{"date":29,"type":30},"2026-07-13","ACTUAL",{"date":32,"type":30},"2006-01-01",{"date":34,"type":19},"2028-06-18",{"name":36,"class":37},"City of Hope Medical Center","OTHER",2,{"id":40,"slug":4,"hasResults":10,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":46,"conditions":47,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":50,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":54,"locationsCount":55},"100053549","NCT06490003","Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma","Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma by Biopsy Specimens.","Inclusion Criteria:\n\n1. Patients who had histologically confirmed esophageal squamous cell carcinoma.\n2. Patients who had undergone chemotherapy.\n3. Patients receiving initial chemotherapy\n4. Written informed consent following full study information is provided to the patient.\n\nExclusion Criteria:\n\n1. Patients for whom a preoperative biopsy sample cannot be obtained\n2. Patients who cannot assess at 2 months later after chemotherapy.\n3. Patients with multiple cancers.",{"count":18,"type":19},"Esophageal cancer remains a disease with a poor prognosis. Chemotherapy is an important part of its treatment, but there are cases in which chemotherapy is ineffective. The investigators aim to develop a model to predict the response to chemotherapy by DNA methylation of preoperative biopsy specimens to identify the chemotherapy ineffective group.",[48,49,25],"Esophageal Squamous Cell Carcinoma","Chemotherapy Effect",{"date":29,"type":30},{"date":52,"type":30},"2004-06-01",{"date":34,"type":19},{"name":36,"class":37},1,{"id":57,"slug":4,"hasResults":10,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":15,"minAge":63,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":75,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":55},"100643279","NCT07631624","Methylated Biomarkers of Smoking as a Selection Tool in Participants for Lung Cancer Screening","MET-SELS","Cohort 1: Volunteers\n\nInclusion Criteria:\n\n* Age: Must be \\> 50 years of age\n* Smoking History: Includes individuals with and without a smoking history\n\nCohort 2: ZORALCS-study participants\n\nInclusion Criteria:\n\n* Age: 55-74 years old\n* Smoking History: Includes individuals with a smoking history",true,"50 Years",{"count":65,"type":19},1000,"INTERVENTIONAL",[68],"NA","The MET-SELS study aims to revolutionize how we identify individuals for lung cancer screening by moving beyond the limitations of self-reported smoking history. Currently, eligibility for low-dose CT (LDCT) scans relies on \"pack-years\"-a metric often compromised by recall bias, under-reporting, and an inability to account for the biological nuances of smoke inhalation or environmental exposure. Consequently, current criteria miss nearly half of incidental lung cancers.\n\nTo bridge this gap, the study investigates DNA methylation as a stable, objective \"biological footprint\" of smoking. Unlike short-term biomarkers like nicotine or CO levels, specific epigenetic changes in genes such as AHRR and F2RL3 persist long after cessation and correlate accurately with cumulative tobacco exposure.\n\nLed by Professor Dr. Annemiek Snoeckx and a multidisciplinary team at UZA and the Centre for Medical Genetics, the research will analyze saliva samples from two groups: roughly 900 participants from the ZORALCS screening trial and 150 volunteers. By comparing saliva-derived genomic signatures against both self-reported data and professional interviews, the team aims to validate a panel of methylation markers that can pinpoint high-risk individuals with far greater precision.\n\nThe ultimate vision for MET-SELS is to implement a population-based \"saliva-first\" triage system, similar to the FIT test used for colorectal cancer. In this model, high-risk candidates would provide a saliva sample at home; only those with a confirmed epigenetic risk profile would be invited for a LDCT scan, significantly increasing the yield of early-stage lung cancer detection while streamlining healthcare resources.",[71,25,72,73,74],"Epigenetics","Lung Cancer Screening","Risk Stratification With Biomarker","Saliva",[76,72,77,78,74],"DNA-methylation","Risk stratification","Smoking","2026-06-03",{"date":81,"type":30},"2026-06-08",{"date":83,"type":30},"2025-10-04",{"date":85,"type":19},"2028-01-01",{"name":87,"class":37},"University Hospital, Antwerp",{"id":89,"slug":4,"hasResults":10,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":10,"sex":15,"minAge":94,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":66,"phases":97,"briefSummary":98,"conditions":99,"keywords":103,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":55},"100500045","NCT05791149","Epigenetic Biomarkers in the Saliva for the Diagnosis of Squamous Cells Carcinoma of the Oral Cavity","EPSACO","Inclusion Criteria:\n\n* Patient group:\n* Patients from the maxillofacial surgery department treated for a histologically confirmed squamous cell carcinoma of the oral cavity\n* Patients whose first-line treatment decision at the multidisciplinary meeting in the service of Maxillofacial Surgery is surgery\n* Patients who have not yet been treated surgically or by neoadjuvant treatment\n* Patients over 18 years old\n* Patients who have provided free and informed consent in writing\n* Patients benefiting from a social security scheme\n\nControl group:\n\n* Patients in the maxillofacial surgery department not covered for head and neck cancer\n* Patients over 18 years old\n* Patients who have provided free and informed consent in writing\n* Patients benefiting from a social security scheme\n* Control group homogeneous with the patient group according to age, sex, tobacco and alcohol consumption\n\nExclusion Criteria:\n\n* Patients with other types of cancer\n* Patients under the age of 18\n* Pregnant or breastfeeding women\n* Patients under guardianship, curators, legal protection or deprived of liberty","18 Years",{"count":96,"type":19},60,[68],"Head and neck squamous cell carcinoma (HNSCC) are malignant tumors originating from the epithelial mucosa of the upper aerodigestive tract. The oral cavity is the most frequent location of HNSCC (oral squamous cell carcinoma: OSCC). Tobacco use and alcohol consumption are the greatest risk factors. The Hauts de France region has one of the highest incidence rates of OSCC. The overall survival of patients with OSCC remains low, with a 5-year overall survival rate of around 60%. In addition to the oncological prognosis, OSCCs and their treatment have a significant impact on the quality of life of patients. An early diagnosis of OSCC is recommended, but it remains difficult. It can be for example challenging to diagnose OSCC in a context of oral premalignant lesions. Identifying objective biomarkers of malignancy would be an advantage and would allow better progress in the field of precision medicine and surgery for these tumors.\n\nThe investigators propose to establish the diagnostic use of an optimized DNA methylation profile detected in the saliva of OSCC patients by comparing these epigenetic marks before and after tumor resection.\n\nThe investigators will construct a consolidated signature of 4 genes whose DNA is subject to methylation and gene expression is restricted to cancer cells, by crossing TCGA analysis with single-cell analysis (single-cell RNA sequencing).\n\nThe investigators propose to analyse DNA methylation of the corresponding genes in the saliva of n=30 OSCC patients recruited for primary surgical resection in the Department of Maxillofacial Surgery vs controls. In addition, the investigators will examine the methylation profiles before \u002F after complete excisional surgery of OSCC. This pilot study will aim to validate the analysis of DNA methylation markers in saliva of OSCC, with the aim of improving the diagnostic precision of OSCC and, secondly, to compare these markers before and after treatment by primary surgery.",[100,101,102,74,25,71],"Oral Squamous Cell Carcinoma","Maxillo-facial Surgery","Biomarkers",[100,104,102,74,25,105],"Maxillo-facial surgery","epigenetics","2026-05-12",{"date":108,"type":30},"2026-05-13",{"date":110,"type":30},"2022-03-03",{"date":112,"type":19},"2027-10",{"name":114,"class":37},"Centre Hospitalier Universitaire, Amiens",{"id":116,"slug":4,"hasResults":10,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":10,"sex":15,"minAge":94,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":124,"conditions":125,"keywords":127,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":55},"100526918","NCT06140992","PaCIFiC-CUP Classifies Cancer of Unknown Primary","PaCIFiC-CUP：Pan-Cancer Integrated Fingerprinting Classifier for Identifying the Origin of Cancer of Unknown Primary: A Multi-Center Prospective Cohort Study","Inclusion Criteria:\n\n1. The patient specimens were obtained from the Sun Yat-sen University Cancer Center and affiliated cooperating centers, with written consent from the patients authorizing the use of the specimens for research purposes.\n2. Following standard assessments (medical history, physical examination, complete blood count, biochemistry, computed tomography scans of the neck, chest, abdomen, and pelvis, targeted evaluations of all symptomatic areas, pathology, and immunohistochemistry), the diagnosis was determined as a primary site unknown tumor (including adenocarcinoma, squamous cell carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma, sarcoma, etc).\n3. The diagnosis was confirmed at the participating institution and the patient had received systemic therapy.\n4. Complete clinical, pathological, and follow-up data for the patients can be obtained.\n5. ECOG performance status score: 0-2 points.\n\nExclusion Criteria:\n\n1. Pregnant or lactating female patients.\n2. Tumor tissue sample size is too small (tumor tissue accounts for \\\u003C70% in the biopsy or slice tissue).\n3. Organ transplant or history of non-autologous (allogeneic) bone marrow or stem cell transplantation.\n4. History of previous tumors, with the current condition being a recurrent tumor.\n5. Hematological malignancies (excluding lymphoma).\n6. Other diseases that may severely impact patient survival, such as severe cardiovascular or cerebrovascular diseases, sepsis, severe trauma or burns, etc.","80 Years",{"count":123,"type":19},120,"This study aims to initially utilize machine learning on pan-cancer DNA methylation data from public databases to construct a DNA methylation classification model (PaCIFiC-CUP, pan-cancer integrated fingerprinting classifier of CUP) for diagnosing various types of cancer, particularly the primary site of cancer of unknown primary. The goal is to achieve diagnosis of cancer pathology type by analyzing the DNA methylation patterns of cancer specimens, thereby guiding subsequent precision treatment for cancer.",[126,25],"Unknown Primary Tumors",[126,128,129,130],"DNA methylation","Large Language Model","Pan-cancer","2026-04-22",{"date":133,"type":30},"2026-04-23",{"date":135,"type":30},"2023-07-01",{"date":137,"type":19},"2026-12-31",{"name":139,"class":37},"Sun Yat-sen University",{"id":141,"slug":4,"hasResults":10,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":10,"sex":147,"minAge":94,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":163,"locationsCount":4},"100615907","NCT07298707","Cervical Cytology DNA Methylation for Endometrial Lesion Screening and Follow-up","A Multicenter Study on Cervical Cytology DNA Methylation for Screening and Follow-up of Endometrial Lesions","EndoMethy-V","Inclusion Criteria:\n\n1. Participants must be 18 years of age or older.\n2. Participants must possess medium-to-high risk factors for endometrial cancer as defined by Chinese consensus guidelines and are scheduled for hysteroscopic evaluation; OR are currently undergoing conservative treatment (e.g., progesterone therapy or endometrial ablation) for endometrial lesions, and have not received chemotherapy.\n3. Participants must be capable and willing to provide written informed consent.\n4. Participants must be willing to undergo at least one follow-up assessment within 1 year.\n5. Participants must have an intact cervix (a history of LEEP or conization is acceptable).\n\nExclusion Criteria:\n\n1. Current treatment for any gynecologic malignancy other than endometrial cancer.\n2. Current or untreated cervical, vaginal, or vulvar intraepithelial neoplasia or carcinoma.\n3. History of total or subtotal hysterectomy, trachelectomy, radical trachelectomy, or pelvic radiotherapy.\n4. Active lower genital tract bleeding.\n5. Immunosuppressed state (e.g., HIV infection, status post organ transplantation).\n6. Failure to undergo the planned hysteroscopic evaluation and follow-up within 1 year after the initial assessment.\n7. Failed hysteroscopic procedure.\n8. Any other condition that, in the opinion of the investigator, makes the participant unsuitable for inclusion in the study.","FEMALE",{"count":149,"type":19},3500,"The goal of this observational study is to evaluate the accuracy of a novel molecular test for screening and monitoring endometrial lesions in women at medium-to-high risk for endometrial cancer.\n\nThe main questions it aims to answer are:\n\n* What is the sensitivity and specificity of the CISENDO test (a DNA methylation test on cervical cytology samples) for detecting histologically confirmed endometrial intraepithelial neoplasia (EIN) or invasive endometrial cancer?\n* How do DNA methylation levels change during the follow-up of endometrial lesions? Researchers will compare the results of the CISENDO test to the results from the standard diagnostic procedure (hysteroscopy with histology) to see if the molecular test can reliably identify high-risk lesions and track disease progression.\n\nParticipants will:\n\n* Provide a residual liquid-based cervical cytology sample for the CISENDO test.\n* Undergo a standard diagnostic hysteroscopy examination (with or without biopsy) for comparison.\n* Some participants will return for follow-up visits at 6 and 12 months for repeat methylation testing and\u002For hysteroscopy to monitor their condition.",[152,25,153,154,155],"Endometrial Neoplasms","Cervical Smears","Early Detection of Cancer","Endometrial Hyperplasia","NOT_YET_RECRUITING","2025-12-09",{"date":159,"type":30},"2025-12-23",{"date":161,"type":19},"2026-01-10",{"date":137,"type":19},{"name":164,"class":37},"Peking Union Medical College Hospital",{"id":166,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":168,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":173,"leadSponsor":175,"locationsCount":38},"100552667",{"count":18,"type":19},[23,24,25],"2025-07-09",{"date":171,"type":30},"2025-07-11",{"date":32,"type":30},{"date":174,"type":19},"2026-06-18",{"name":36,"class":37},{"id":177,"slug":4,"hasResults":10,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":46,"conditions":179,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":182,"leadSponsor":183,"locationsCount":55},"100553739",{"count":18,"type":19},[48,49,25],{"date":171,"type":30},{"date":52,"type":30},{"date":174,"type":19},{"name":36,"class":37},{"id":185,"slug":4,"hasResults":10,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":10,"sex":15,"minAge":94,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":192,"conditions":193,"keywords":196,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":55},"100495957","NCT05737953","Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples","Construction of Molecular Diagnostic Marker Models for Pancreatic Cystic Tumors Based on CfDNA Methylation Sequencing and Proteomic Analysis of Pancreatic Cystic Fluid Samples","Inclusion Criteria:\n\n* Subjects are ≥ 18 years old, regardless of gender;\n* Preoperative imaging examination (EUS, CT, MRI) diagnosed cystic mass of pancreas and suspected cystic tumor;\n* Subjects voluntarily accepted radical resection of pancreatic cystic tumors;\n* Subjects or family members voluntarily sign the informed consent form for clinical research.\n\nExclusion Criteria:\n\n* The excised sample does not contain cystic components, or the cystic fluid cannot be collected;\n* Receive tumor-related treatment (radiotherapy, chemotherapy, immunotherapy, etc.) before operation;\n* Receive antibiotic treatment within 1 week before operation;\n* Subjects refused to accept radical resection of pancreatic cystic tumor, or had any situation that they could not accept radical resection of pancreatic cystic tumor;\n* The subjects or their families refused to sign the informed consent form for clinical research.",{"count":191,"type":19},100,"The goal of this observational study is to test in patients with cystic tumor of pancreas. The main questions it aims to answer are:\n\nScreening of molecular diagnostic markers for pancreatic cystic tumors by cfDNA methylation sequencing of pancreatic cystic fluid and proteomic assays to distinguish benign from malignant and mucinous\u002Fnon-mucinous, correlate with pathological features, and find molecular features associated with the degree of malignancy.\n\nParticipants will Provide post-operative cyst fluid specimens.",[194,25,195],"Pancreatic Neoplasms","Proteome",[197],"Pancreas cystic neoplasm","2025-02-07",{"date":200,"type":30},"2025-02-11",{"date":202,"type":30},"2023-03-01",{"date":204,"type":19},"2025-07-31",{"name":206,"class":37},"Zhaoshen Li",{"id":208,"slug":4,"hasResults":10,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":10,"sex":147,"minAge":94,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":55},"100558963","NCT06557954","Cervical Cytology DNA Methylation for Cervical Cancer Screening","Cervical Cytology DNA Methylation for Cervical Cancer Screening: A Real Word Study","Inclusion Criteria:\n\n* Aged 18 years or older\n* With uterine cervix intact\n* Given consents to participate the study\n* With detailed follow-up outcomes\n\nExclusion Criteria:\n\n* Not meeting all of the inclusion criteria",{"count":214,"type":19},30000,"Cervical cancer represents one of the foremost causes of cancer-related morbidity and mortality among women worldwide. Given the current limitations, such as the low specificity of human papillomavirus (HPV) testing and the relatively low sensitivity of cytological examinations, there is a pressing need for a novel, non-invasive, safe, and precise screening method. This study aims to undertake a multicentre, real-world investigation, incorporating at least 10 sub-centres and enrolling 30,000 participants. Histopathological examination results will serve as the 'gold standard' for evaluating the screening efficacy of human PAX1 and JAM3 gene methylation assays (PAX1m\u002FJAM3m), HPV testing, and cytological examinations. Furthermore, the study seeks to elucidate the relationship between DNA methylation levels and persistent HPV infection, while also assessing the applicability of PAX1m\u002FJAM3m across diverse clinical settings. By focusing on alterations in DNA methylation levels within cervical exfoliated cells as the primary research trajectory, this study aspires to furnish novel insights and theoretical foundations for the prevention and management of cervical cancer, targeting PAX1m\u002FJAM3m. The ultimate objective is to facilitate the clinical implementation of an enhanced cervical cancer screening protocol, thereby addressing the deficiencies of current screening methodologies, achieving greater precision in cervical cancer screening, and effectively reducing the incidence of cervical cancer while mitigating the risks of overdiagnosis and overtreatment.",[217,25,218,219,220,221],"Cervical Cancer","Cytology","Human Papillomavirus Infection","Cervical Intraepithelial Neoplasia","Cancer Screening","2024-08-15",{"date":224,"type":30},"2024-08-19",{"date":226,"type":19},"2024-09-01",{"date":228,"type":19},"2026-10-01",{"name":230,"class":37},"Lei Li",""]